rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Chrysa Mineo

Director

Company insider

Files Form 4 as: Director, Cidara Therapeutics; SVP, Corporate Development, Receptos.

Every Form 4 they filed

In numbers

Trades disclosed
47
Buys
2
Sells
1
Bought
$74K
Sold
$3.3M
Companies
2
Companies where not an officer
1
First trade
14 May 2013
Last trade
7 Jan 2026
Last filed
7 Jan 2026

Companies traded

Where they are an officer
ReceptosOfficer · last 27 Aug 20150 buys · 1 sell
Everywhere else they filed: board seats, 10% stakes, other companies
Cidara TherapeuticsDirector · Biotechnology · last 7 Jan 20262 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
02Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
7 Jan 2026filed 7 Jan 2026Cidara TherapeuticsBiotechnologySEC FORM 4 Code D$735K3,320 at $221.50filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—19,000filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—11,100filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—1,000filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—550filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivativeSEC FORM 4 Code D—1,000filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivativeSEC FORM 4 Code D—550filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivativeSEC FORM 4 Code D—550filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivativeSEC FORM 4 Code D—875filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivativeSEC FORM 4 Code D—875filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivativeSEC FORM 4 Code D—1,400filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivativeSEC FORM 4 Code D—2,125filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivativeSEC FORM 4 Code D—2,125filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivativeSEC FORM 4 Code D—19,000filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivativeSEC FORM 4 Code D—11,100filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—550filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—875filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—875filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—1,400filing
7 Jan 2026filed 7 Jan 2026Cidara Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—2,125filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Not placed3

Buys in green, sells in red, by the company’s sector.

Related people

Nobody else traded the same names lately.